LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)

MONARCH 2 led to abemaciclib + fulvestrant approval in pts with HR+, HER2- ABC with disease progression on prior endocrine therapy and demonstrated significant OS benefit. MONARCH 3 led to abemaciclib + NSAI approval as initial therapy in postmenopausal pts with HR+, HER2- ABC with significant improvement in progression-free survival (PFS). Here we report the second interim analysis (IA2) OS results for MONARCH 3, an analysis included in the European Product Label by request of EMA.